Incretin-based therapies — particularly GLP-1 receptor agonists like semaglutide — reduce cardiovascular events in overweight and obese non-diabetic patients, but the mechanistic pathway remains contested. While these agents lower inflammatory and oxidative stress biomarkers and demonstrate anti-atherosclerotic effects in animal models, human vascular imaging data are inconclusive, and whether direct receptor-mediated anti-inflammatory action meaningfully contributes beyond weight and metabolic improvement cannot yet be separated.
The clinical significance here cuts in two directions. First, the cardiovascular benefit of semaglutide in non-diabetic obesity — confirmed in SELECT trial data — is genuinely paradigm-expanding, moving GLP-1 agonists beyond glucose management into broad cardiometabolic protection. Second, and more cautionary, this review exposes a persistent gap between biomarker associations and proven mechanisms. The field has repeatedly mistaken inflammation marker reduction for clinically meaningful anti-inflammatory action — a trap illustrated by the CANTOS trial with canakinumab, which proved inflammation causal but yielded modest, population-specific benefit. That GLP-1 agents reduce CRP and IL-6 is encouraging, but mechanistic attribution remains premature without dedicated human intervention trials with vascular endpoints. For clinicians, the practical implication is clear: GLP-1 receptor agonists are now first-line tools for residual cardiovascular risk in obese patients regardless of diabetes status. For researchers, the mechanistic question — weight loss versus direct vascular effect — remains genuinely open and worth pursuing.
